Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Market Intelligence

Set Alert for Market Intelligence

June Sees UK Ivabradine Prices More Than Treble

Ivabradine exhibited interesting pricing dynamics in the UK in June, with the average cost of the heart failure treatment more than trebling despite the lowest offer in the market remaining stable.

Market Intelligence Pricing Strategies

France’s Gemme Unveils Three-Point Plan To Bolster Biosimilars

Fresh impetus is needed to help biosimilars achieve their full potential in France, according to off-patent industry association Gemme. The organization has unveiled a three-point plan to bolster the sector that includes proposals to allow pharmacists to substitute biosimilars for brand prescriptions under certain circumstances.

Biosimilars France

New BGMA Chief Battles Twin Pressures Of COVID And Brexit

When Mark Samuels took over leadership of the BGMA earlier this year, he was immediately forced to grapple with the twin pressures of Brexit and the COVID-19 pandemic. However, he tells Generics Bulletin in an exclusive interview, the UK off-patent industry has succeeded in maintaining supply against this difficult backdrop and deserves a more coherent government strategy to support the sector.

United Kingdom Brexit

UK Gentamicin Prices Rocket Up In May

Gentamicin prices saw huge increases in the UK in May, with the average shooting up by almost 600%.

Market Intelligence Pricing Strategies

US Sees Increasing Diversity In Generic Formulations

Over the past five years, around a tenth of the US generics market’s total value has been ceded by oral solid dose generics to other formulations, IQVIA’s Doug Long told the AAM’s “Access!” annual meeting at the end of May.

Market Intelligence United States

Educational Barriers Are Still Holding Back Biosimilars

Panellists at a recent webinar hosted by Sandoz on “unlocking the potential of biosimilars” agreed that biologics are increasingly advancing to first-line treatments. However, industry and regulatory leaders cited lack of education as a significant barrier to biosimilars uptake. The experts also offered reasons for the reduced uptake in immunology biosimilars compared to oncology. 

Europe Biologics

Samsung Bioepis Breaks Down Biosimilar Experiences In Europe And US

Samsung Bioepis reiterated that the US pharma market is “the most fragmented and the most complicated market in the world” as it discussed its biosimilar fortunes in Europe.

Biosimilars Market Intelligence

Etoricoxib Leads Biggest UK Price Rises In April

Etoricoxib led the steepest price rises for UK generics in April, with the non-steroidal anti-inflammatory drug seeing average prices almost double.

Market Intelligence Pricing Strategies

GBMA Welcomes Australian Investment

Australia’s GBMA off-patent industry association has welcomed the announcement of significant healthcare investment in the country’s federal budget.

Australia Policy
See All
UsernamePublicRestriction

Register

;